In a challenging year for biotech firms, Pyxis Oncology’s stock has touched a new 52-week low, sinking to $0.98. According to... Tuesday, Pyxis Oncology Inc. (NASDAQ:PYXS) saw its price target ...

BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced ...

Pyxis Oncology Inc. research and ratings by Barron's. View PYXS revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

In a report issued on May 15, Leonid Timashev from RBC Capital maintained a Buy rating on Pyxis Oncology, with a price target of $8.00. The company’s shares closed last Monday at $1.23 ...

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an ...

Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades ...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investing.com - Pyxis Oncology (NASDAQ: PYXS) reported first quarter EPS of $-0.54, $0.36 better than the analyst estimate of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...